Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib Followed by Sunitinib vs Sunitinib Followed by Sorafenib in First-Line Advanced/Metastatic Renal Cell Carcinoma
DRKS00003884Phase 3Completed
- Sponsor
- Sponsor
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sorafenib and sunitinib in renal cell carcinoma (RCC), kidney cancer and renal pelvis cancer (2 arms), sponsored by Sponsor. Started Apr 2012; status: completed.
02
Drugs
sorafenibsunitinib
03
Conditions
renal cell carcinoma (RCC)kidney cancerrenal pelvis cancer
Beyond the preview
Go deeper on DRKS00003884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00003884.